PVP-I Nasal Sprays and SARS-CoV-2 Nasopharyngeal Titers (for COVID-19)

Trial ID or NCT#

NCT04347954

Status

not recruiting iconNOT RECRUITING

Purpose

The study aims to determine the safety and efficacy of povidone-iodine (PVP-I) containing nasal sprays as compared to isotonic saline nasal sprays in COVID-19 positive patients. The primary outcome measure is SARS-CoV-2 viral titers in the nasal cavity and nasopharynx. In vitro studies have shown PVP-I to be highly virucidal against the viruses which cause SARS and MERS. Additionally, clinical studies have shown PVP-I saline sprays to be well tolerated in human subjects. PVP-I oral rinses and sprays have been trialed as methods to reduce the incidence and symptoms of viruses which cause the "common cold."

Official Title

Effect of PVP-I Nasal Sprays vs Normal Saline Nasal Sprays on SARS-CoV-2 Nasopharyngeal Titers

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No
Inclusion Criteria:
  1. - Diagnosis of COVID-19 by lab test within 5 days of study participation
Exclusion Criteria:
  1. - Allergy to "iodine," shellfish, or food dye - Receiving intranasal steroids - Sinus surgery within 30 days of beginning the study - Intubated at the time of enrollment - Pregnancy - Participation in other COVID-19 studies - to be determined on a case by case basis
View All Criteria
Show Less

Investigator(s)

Jayakar V. Nayak, MD, PhD
Jayakar V. Nayak, MD, PhD
Head and neck surgeon, Rhinologist, Otolaryngologist, Ear, nose, and throat specialist
Associate Professor of Otolaryngology - Head & Neck Surgery (OHNS) and, by courtesy, of Neurosurgery

Contact us to find out if this trial is right for you.

Contact

Peter H Hwang, MD
650-725-6500

View on ClinicalTrials.gov